All In Biotech

Drug Trial Radar · NCT01437787

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Last checked: Nov 21, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 289 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

289

Actual

Start

Dec 31, 2011

Primary completion

Jun 30, 2014

Study completion Jun 30, 2014

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Sep 21, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: * To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance imaging (MRI) (or computed tomography scan in patients with contraindications for MRI). Secondary Objectives: * To evaluate the effect on Myelofibrosis (MF)-associated symptoms (key MF symptoms) as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary. * To evaluate the Overall Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo. * To evaluate the Progression Free Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo. * To evaluate the durability of splenic response. * To evaluate the safety of IMP.

Conditions

  • Hematopoietic Neoplasm

Interventions

  • SAR302503Drug

    Pharmaceutical form:capsule Route of administration: oral

  • PlaceboDrug

    Pharmaceutical form:capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response Rate (RR): Percentage of Participants Who Had a >=35% Reduction From Baseline in Volume of Spleen Size at The End Cycle 6Time frame: Baseline, Week 24

Locations

101 sites in 25 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840014

    Scottsdale, Arizona

  • Investigational Site Number 840001

    La Jolla, California

  • Investigational Site Number 840012

    La Jolla, California

  • Investigational Site Number 840006

    Los Angeles, California

  • Investigational Site Number 840013

    Baton Rouge, Louisiana

  • Investigational Site Number 840008

    Rochester, Minnesota

  • Investigational Site Number 840009

    Newark, New Jersey

  • Investigational Site Number 840002

    Canton, Ohio

  • Investigational Site Number 840004

    Houston, Texas

  • Investigational Site Number 036001

    Box Hill, Australia

  • Investigational Site Number 036005

    Herston, Australia

  • Investigational Site Number 036003

    Randwick, Australia

  • Investigational Site Number 036004

    Tweed Heads, Australia

  • Investigational Site Number 036002

    Wodonga, Australia

  • Investigational Site Number 040001

    Vienna, Austria

  • Investigational Site Number 056003

    Antwerp, Belgium

  • Investigational Site Number 056001

    Leuven, Belgium

  • Investigational Site Number 076002

    Jaú, Brazil

  • Investigational Site Number 076004

    Porto Alegre, Brazil

  • Investigational Site Number 076001

    Rio de Janeiro, Brazil

  • Investigational Site Number 124001

    Montreal, Canada

  • Investigational Site Number 124003

    Montreal, Canada

  • Investigational Site Number 124002

    Saint John, Canada

  • Investigational Site Number 250006

    Marseille, France

  • Investigational Site Number 250005

    Nantes, France

  • Investigational Site Number 250004

    Nîmes, France

  • Investigational Site Number 250002

    Pierre-Bénite, France

  • Investigational Site Number 250007

    Poitiers, France

  • Investigational Site Number 250003

    Toulouse, France

  • Investigational Site Number 250001

    Villejuif, France

  • Investigational Site Number 276006

    Aachen, Germany

  • Investigational Site Number 276007

    Bonn, Germany

  • Investigational Site Number 276008

    Dresden, Germany

  • Investigational Site Number 276001

    Mannheim, Germany

  • Investigational Site Number 348002

    Budapest, Hungary

  • Investigational Site Number 348001

    Debrecen, Hungary

  • Investigational Site Number 348007

    Győr, Hungary

  • Investigational Site Number 348006

    Kecskemét, Hungary

  • Investigational Site Number 348003

    Miskolc, Hungary

  • Investigational Site Number 372002

    Dublin, Ireland

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.